Jan. 20, 2016:
The Big Ten Cancer Research Consortium‘s “Across the Consortium” is your front-row seat to all the latest action in cancer research conducted by our member institutions.
- Home
- About Us
- News & Events
- Leadership
- Raymond J. Hohl, MD, PhD
- Raphael E. Pollock, MD, PhD
- Monika Joshi, MD, MRCP
- Oana Danciu, MD
- Timothy Fan, PhD, DVM
- Nabil Adra, MD
- Muhammad Furqan, MD
- Vu Hong Duong, MD, MS
- Aki Morikawa, MD, PhD
- Daniel Isaac, DO
- Veronika Bachanova, MD, PhD
- Vijaya Raj Bhatt, MBBS, MS
- Jyoti Patel, MD
- John L. Hays, MD, PhD
- Patrick C. Ma, MD, MSc
- Thomas G. Sors, PhD
- Salma Jabbour, MD
- Kari Wisinski, MD
- Member Institutions
- University of Illinois Cancer Center
- The Cancer Center at Illinois
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
- Holden Comprehensive Cancer Center, University of Iowa
- The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
- University of Michigan Rogel Cancer Center
- Michigan State University Cancer Research
- Masonic Cancer Center, University of Minnesota
- Fred & Pamela Buffett Cancer Center (University of Nebraska)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
- Penn State Cancer Institute
- Purdue University Institute for Cancer Research
- Rutgers Cancer Institute of New Jersey
- University of Wisconsin Carbone Cancer Center
- Clinical Research
- Current Trials
- Research Criteria
- Diversity Resources
- Adolescent and Young Adult Clinical Trial Working Group
- Basket Trial Clinical Trial Working Group
- Bone Marrow / Stem Cell Transplant Clinical Trial Working Group
- Breast Cancer Clinical Trial Working Group
- Comparative Oncology Clinical Trial Working Group
- Correlative Sciences Clinical Trial Working Group
- Gastrointestinal Clinical Trial Working Group
- Genitourinary Clinical Trial Working Group
- Gynecologic Clinical Trial Working Group
- Head and Neck Clinical Trial Working Group
- Lymphoid Malignancies Clinical Trial Working Group
- Melanoma/Cutaneous Oncology Clinical Trial Working Group
- Multiple Myeloma Clinical Trial Working Group
- Myeloid Malignancies Clinical Trial Working Group
- Neuro-Oncology Clinical Trial Working Group
- Population Science Clinical Trial Working Group
- Sarcoma Clinical Trial Working Group
- Thoracic Clinical Trial Working Group
- Donate
- Contact
News & Developments
Big Ten cancer centers making gains against cervical cancer
Jan. 12, 2016 According to the National Cancer Institute, an estimated 12,900 new cases of cervical cancer occurred in the United States in 2015. The disease also caused an estimated 4,100 deaths. But the dawn of 2016 ushers in exciting opportunities for a new year of progress in cancer research, prevention, and treatment. January is National Cervical Cancer Awareness Month, and member institutions of the Big Ten Cancer Research Consortium are leading the fight against this highly preventable, highly treatable cancer. Discovering disparity: Study addresses disparity in cervical cancer deaths While studying cervical cancer statistics compiled by the...
Member Feature: University of Illinois Cancer Center
Jan. 4, 2016: A conversation with Arkadiusz Dudek, MD, PhD, professor of medicine, hematology/oncology, at the University of Illinois College of Medicine. Dr. Dudek is a member of both the University of Illinois Cancer Center and the BTCRC Steering Committee. Q: How do you think cancer research will change in the next 10 to 20 years? Portable technology is changing research every day. From apps to scanners, information transmission is faster than ever before. In development at the University of Illinois is a portable blood drop test for lung cancer screening. The way a drop of blood can alter the course of daily treatment for a...
Across the Consortium – December 2015
Dec. 18, 2015: As the year is winding down Big Ten university researchers have not lost their momentum. As we look back over this past year, great accomplishments along with generous grants and gifts are the hallmarks worthy of celebration. Big Ten CRC members are committed to improving treatment paradigms, and they continue to do just that through rigorously investigating correlations with far-reaching effects. A few examples include new insight into restoring cancer suppressor activity to damaged genes and identifying specific genes correlated with lung cancer tumor formation and metastasis; a comprehensive study that shows the relationship of mastectomy to survival; and new developments that promise to revolutionize clinical tests used in diagnosing and treating different cancers. We look forward...
2015 Highlights in Review
Dec. 11, 2015: Thank you to all who contributed to the Big Ten Cancer Research Consortium’s success over the past year. Together we have achieved new milestones, increased participation within clinical trial working groups, and expanded both the number and diversity of concepts in the consortium’s pipeline. During this holiday season, we are grateful for what we have accomplished. Following are just a few highlights: Read More
Big Ten CRC FAQ: Regulatory and Safety
Dec. 11, 2015: What are the responsibilities of Big Ten CRC regulatory managers? Big Ten CRC regulatory managers assist with all aspects of regulatory issues related to Big Ten CRC research, including interactions with consortium members, institutional review boards, and regulatory agencies. Regulatory services include: Read More
Member Feature: Holden Comprehensive Cancer Center
Dec. 1, 2015: A conversation with George Weiner, MD, director of Holden Comprehensive Cancer Center at the University of Iowa and the C.E. Block Chair of Cancer Research and professor of internal medicine at the University of Iowa, which is a member of the Big Ten Cancer Research Consortium. Dr. Weiner has led a statewide collaborative to reduce the burden of cancer in Iowa, served on committees within the National Cancer Institute, and is currently serving a two-year term as president of the Association of American Cancer Institutes (AACI), which comprises 92 leading cancer research centers in the United States. Q: How do you think cancer research will change in the next 10 to 20 years? Rapid changes in cancer...
Across the Consortium – November 2015
Nov. 13, 2015: Big Ten Cancer Research Consortium members understand it takes the whole team to win the battle against cancer. By leading efforts to enhance diversity, members and consortium leadership are working hard to tackle disparities in clinical trial participation. Last month Susan Goodin, executive officer of the Big Ten Cancer Research Consortium, had the opportunity to be a panelist at a forum on clinical trial diversity in Chicago. Also in this month’s edition of Across the Consortium, we highlight the many ways our members are pushing the boundaries of science and technology in order to improve diagnosis, treatment, and other cancer related experiences. Read More
Big Ten investigators tackling lung, pancreatic, stomach cancer
Nov. 2, 2015: November is the national month of awareness for pancreas, stomach, and lung cancers. Within the Big Ten Cancer Research Consortium, member institutions are tackling these cancers through innovative multidisciplinary efforts that leverage the scientific expertise of Big Ten universities.
Innovation in Early Detection
Vadim Backman, PhD, Walter Dill Scott Professor of Biomedical Engineering in the McCormick School of Engineering at Northwestern University believes if there were regular, reliable screening for lung cancer and other cancers, there could be a significant reduction in cancer-related deaths. The McCormick School of Engineering reports thatMember Feature: IU Simon Cancer Center
Nov. 2, 2015: A conversation with Patrick J. Loehrer, Sr., MD, director of the Indiana University Melvin and Bren Simon Cancer Center, which is a member of the Big Ten Cancer Research Consortium: Q: How do you think cancer research will change in the next 10 or 20 years? Cancer therapy, like much of medicine, is quite empiric. Understanding greater details of what drives tumors to grow will be greatly enhanced in the next several years. We are in the onset of the age of cancer informatics and immunotherapy. The information overload will need to be simplified into bite-size pieces of relevant information that can better identify the complex biological engineering of the cancer cell that nature has designed. Immunotherapy is already unleashing tremendous...
Illinois
University of Illinois
Indiana
Indiana University
Iowa
University of Iowa
Maryland
University of Maryland
Michigan
University of Michigan
Michigan State
Michigan State
Minnesota
University of Minnesota
Nebraska
University of Nebraska
Northwestern
Northwestern University
Ohio State
Penn State
Penn State University
Purdue
Purdue University
Rutgers
Rutgers State University
Wisconsin
University of Wisconsin
UIC
University of Illinois at Chicago
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube